Semaglutide and Tirzepatide for Treating Fatty Liver Disease with Inflammation: Current Options, Future Developments, and Gaps

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form affect a growing number of individuals, particularly those with obesity.

• MASLD is associated with obesity, insulin resistance, and cardiometabolic diseases.
• Current management primarily relies on lifestyle changes, which often do not result in lasting improvement.
• There is a need for effective pharmacologic therapies to manage these conditions.

Simplified